Tiziana Life Sciences (US) (TLSA) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Tiziana Life Sciences reports promising results from its Expanded Access Program, with 70% of multiple sclerosis patients experiencing significant improvements in fatigue after six months of treatment with intranasal foralumab. The study found all participants either stabilized or improved in key clinical measures, indicating a potential new therapeutic option for managing symptoms associated with the disease.
For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.